Shanghai Henlius Biotech (HKG:2696) said the investigational new drug application for a phase 1 clinical trial of HLXTE-HAase02 was approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The pharmaceutical firm will begin the relevant study in the Chinese Mainland once conditions are met.
HLXTE-HAase02 is intended for the development of subcutaneous drug products, helping the drugs achieve more effective subcutaneous delivery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments